JP7748933B2 - 抗dll3キメラ抗原受容体及びその使用 - Google Patents

抗dll3キメラ抗原受容体及びその使用

Info

Publication number
JP7748933B2
JP7748933B2 JP2022502899A JP2022502899A JP7748933B2 JP 7748933 B2 JP7748933 B2 JP 7748933B2 JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022502899 A JP2022502899 A JP 2022502899A JP 7748933 B2 JP7748933 B2 JP 7748933B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
dll3
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542543A5 (cg-RX-API-DMAC7.html
JP2022542543A (ja
Inventor
タオ チャオ
ユエンユエン ペン
アン タン
スウジャン ワン
シュワイ ヤン
ワン チャン
シュー ウー
ルイドン ハオ
Original Assignee
レジェンド バイオテック アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジェンド バイオテック アイルランド リミテッド filed Critical レジェンド バイオテック アイルランド リミテッド
Publication of JP2022542543A publication Critical patent/JP2022542543A/ja
Publication of JP2022542543A5 publication Critical patent/JP2022542543A5/ja
Priority to JP2025015341A priority Critical patent/JP7894963B2/ja
Priority to JP2025156914A priority patent/JP2026001061A/ja
Application granted granted Critical
Publication of JP7748933B2 publication Critical patent/JP7748933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022502899A 2019-07-17 2020-07-17 抗dll3キメラ抗原受容体及びその使用 Active JP7748933B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025015341A JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019096360 2019-07-17
CNPCT/CN2019/096360 2019-07-17
CN2020090587 2020-05-15
CNPCT/CN2020/090587 2020-05-15
PCT/CN2020/102717 WO2021008610A1 (en) 2019-07-17 2020-07-17 Anti-dll3 chimeric antigen receptors and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025015341A Division JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Division JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Publications (3)

Publication Number Publication Date
JP2022542543A JP2022542543A (ja) 2022-10-05
JP2022542543A5 JP2022542543A5 (cg-RX-API-DMAC7.html) 2023-07-21
JP7748933B2 true JP7748933B2 (ja) 2025-10-03

Family

ID=74210175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022502899A Active JP7748933B2 (ja) 2019-07-17 2020-07-17 抗dll3キメラ抗原受容体及びその使用
JP2025015341A Active JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Pending JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025015341A Active JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Pending JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Country Status (9)

Country Link
US (2) US12421292B2 (cg-RX-API-DMAC7.html)
EP (2) EP4527466A3 (cg-RX-API-DMAC7.html)
JP (3) JP7748933B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035367A (cg-RX-API-DMAC7.html)
CN (4) CN118420777A (cg-RX-API-DMAC7.html)
AU (1) AU2020314509A1 (cg-RX-API-DMAC7.html)
CA (1) CA3146019A1 (cg-RX-API-DMAC7.html)
TW (2) TW202535924A (cg-RX-API-DMAC7.html)
WO (1) WO2021008610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180215A1 (en) 2020-03-12 2021-09-16 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
US20240150456A1 (en) * 2021-04-02 2024-05-09 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024006281A2 (en) * 2022-06-28 2024-01-04 Carisma Therapeutics Inc. Switch receptors and modified immune cells
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Dll3抗原結合構築物
US20260061051A1 (en) * 2022-08-26 2026-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
CN115820698B (zh) * 2022-11-22 2025-01-21 浙江康佰裕生物科技有限公司 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用
CN116004547B (zh) * 2023-03-06 2025-04-25 浙江康佰裕生物科技有限公司 一种辐照car-t细胞及其制备方法与应用
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
KR20260079181A (ko) * 2023-09-26 2026-06-01 레전드 바이오테크 유에스에이, 인크. Dll3 결합 모이어티 및 이의 용도
CN122094981A (zh) 2023-10-16 2026-05-26 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
WO2025201493A1 (zh) * 2024-03-29 2025-10-02 诺纳生物(苏州)有限公司 Dll3结合分子及其用途
WO2025212519A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2025240849A1 (en) * 2024-05-16 2025-11-20 The Brigham And Women's Hospital, Inc. Trem2 chimeric antigen receptors and uses thereof
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026052061A1 (en) * 2024-09-05 2026-03-12 Nanjing Legend Biotech Co., Ltd. Adoptive cell compositions
WO2026051938A1 (en) * 2024-09-05 2026-03-12 Therorna Shanghai Co., Ltd. Circular rna encoding chimeric antigen receptors targeting dll3 and the use thereof
CN119708238B (zh) * 2025-02-27 2025-07-04 昕传生物科技(北京)有限公司 靶向dll3的抗体、嵌合抗原受体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506981A (ja) 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗dll3キメラ抗原受容体および使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
CA3034691A1 (en) 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
JP2020517263A (ja) 2017-04-19 2020-06-18 ユニバーシティ オブ サザン カリフォルニア がんを治療するための組成物及び方法
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
US20220025037A1 (en) 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
CR20200539A (es) 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506981A (ja) 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗dll3キメラ抗原受容体および使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Hematology & Oncology,2019年06月,12:61,pp. 1-8,https://doi.org/10.1186/s13045-019-0745-2

Also Published As

Publication number Publication date
JP2025069305A (ja) 2025-04-30
CN114072427A (zh) 2022-02-18
JP2026001061A (ja) 2026-01-06
EP4527466A3 (en) 2025-06-18
AU2020314509A1 (en) 2022-01-06
US20220249563A1 (en) 2022-08-11
TW202116812A (zh) 2021-05-01
TWI883026B (zh) 2025-05-11
US12421292B2 (en) 2025-09-23
CA3146019A1 (en) 2021-01-21
CN118496374A (zh) 2024-08-16
JP7894963B2 (ja) 2026-07-24
TW202535924A (zh) 2025-09-16
US20260078166A1 (en) 2026-03-19
CN114072427B (zh) 2024-04-26
CN117106099A (zh) 2023-11-24
EP3999550A1 (en) 2022-05-25
CN118420777A (zh) 2024-08-02
JP2022542543A (ja) 2022-10-05
EP4527466A2 (en) 2025-03-26
EP3999550A4 (en) 2023-09-06
KR20220035367A (ko) 2022-03-22
WO2021008610A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP7000660B2 (ja) Ror1抗体組成物及び関連の方法
EP4267617A1 (en) Human ccr8 binders
TW201932490A (zh) 針對pd-1之單域抗體及其變異體
TW201946655A (zh) 新型抗體分子、其製備方法及其用途
CN111727057A (zh) 与lag3和pd1结合的治疗分子
JP7830621B2 (ja) 抗-b7-h4/抗-4-1bb二重特異的抗体およびこれの用途
JP2024508207A (ja) がんに対する組み合わせ治療におけるltbrアゴニスト
WO2023236991A1 (zh) 靶向her2,pd-l1和vegf的三特异性抗体
US20230265185A1 (en) Anti-cd22 single domain antibodies and therapeutic constructs
HK40110214A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40110781A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40098926A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40065826A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40065826B (en) Anti-dll3 chimeric antigen receptors and uses thereof
KR20260016889A (ko) B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체
HK40101561A (en) Human ccr8 binders
WO2023031300A1 (en) Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
HK40129808A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
CN116888156A (zh) 非阻断性人ccr8结合剂
CN116964091A (zh) 人ccr8结合剂
HK40103081A (en) Murine cross-reactive human ccr8 binders
CN116284406A (zh) 一种pd-1结合蛋白及其应用
HK40102183A (en) Non-blocking human ccr8 binders
HK40108283A (en) Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230712

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250922

R150 Certificate of patent or registration of utility model

Ref document number: 7748933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150